Fundamental Analysis of NAVIDEA BIOPHARMACEUTICALS I(NYSEARCA:NAVB) stock

Fundamental Rating

Taking everything into account, NAVB scores 0 out of 10 in our fundamental rating. NAVB was compared to 588 industry peers in the Biotechnology industry. NAVB has a bad profitability rating. Also its financial health evaluation is rather negative. NAVB has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

NAVB had negative earnings in the past year.

In the past year NAVB has reported a negative cash flow from operations.

In the past 5 years NAVB always reported negative net income.

In the past 5 years NAVB reported 4 times negative operating cash flow.

1.2 Ratios

NAVB has a worse Return On Assets (-209.43%) than 93.23% of its industry peers.

		Industry Rank	Sector Rank
ROA	-209.43%
ROE	N/A
ROIC	N/A

ROA(3y)-239.03%

ROA(5y)-242.07%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NAVB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NAVB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NAVB has been increased compared to 1 year ago.

NAVB has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, NAVB has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -70.66, we must say that NAVB is in the distress zone and has some risk of bankruptcy.

NAVB has a Altman-Z score of -70.66. This is amonst the worse of the industry: NAVB underperforms 98.18% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-70.66

ROIC/WACCN/A

WACC9.82%

2.3 Liquidity

A Current Ratio of 0.84 indicates that NAVB may have some problems paying its short term obligations.

With a Current ratio value of 0.84, NAVB is not doing good in the industry: 92.90% of the companies in the same industry are doing better.

NAVB has a Quick Ratio of 0.84. This is a bad value and indicates that NAVB is not financially healthy enough and could expect problems in meeting its short term obligations.

NAVB has a Quick ratio of 0.79. This is amonst the worse of the industry: NAVB underperforms 93.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.84
Quick Ratio	0.79

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NAVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.35%.

NAVB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.65%.

The Revenue for NAVB have been decreasing by -48.49% on average. This is quite bad

EPS 1Y (TTM)-39.35%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q221.1%

Revenue 1Y (TTM)-87.65%

Revenue growth 3Y-53.62%

Revenue growth 5Y-48.49%

Revenue growth Q2Q-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NAVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NAVB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NAVIDEA BIOPHARMACEUTICALS I

NYSEARCA:NAVB (10/5/2023, 7:04:00 PM)

0.0779

0 (-2.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap7.80M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-209.43%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.84
Quick Ratio	0.79
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-39.35%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-87.65%

Revenue growth 3Y-53.62%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NAVIDEA BIOPHARMACEUTICALS I (NAVB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens